COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.

Start Date01 Jun 2026

Sponsor / Collaborator

Verrica Pharmaceuticals, Inc.

[+5]

NCT07457918

/ RecruitingPhase 3

COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are:
* To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in Japan) by assessing concomitant medication use, and adverse events (AEs), including expected local skin reactions (LSRs).
* To evaluate the efficacy of continued skin application of YCANTH (VP-102/TO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments.
Participants with eligible common warts present will receive YCANTH (VP-102/TO-208) with an interval of 21 (± 4) days between applications until there is a wart count of zero (ie, completed clearance has been achieved) or a maximum of 4 additional treatments. Participants with complete clearance will attend Observation Visits at intervals of 42 (± 4) days without treatment. Participants who develop a new wart after having a wart count of zero will resume Treatment Visits every 21 (± 4) days for a maximum of 4 additional treatments. All subjects will attend visits until the End-of-Study (EOS) Visit, which is on Day 378 (0/+ 8 days).
If participants still have warts present after 4 additional treatments of YCANTH (VP-102/TO-208) the wart(s) will be discontinued from study and participants will be allowed to seek treatment but should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that receive(d) study drug treatment . The exact interval of Treatment Visits will be determined by evaluation of the treatment site, taking into account any ongoing local skin reactions (LSRs), which are defined as temporary application site:
vesiculation, pain, pruritus, scabbing, erythema, discoloration, dryness, edema and erosion that is expected and consistent with historical treatment with YCANTH (VP-102/TO-208). Participants may receive treatment until all treatable common warts are clear, up to a maximum of 4 treatment sessions, or until Day 357, whichever occurs first.
Treatment:
For participants with warts present at the time of study entry, the first treatment application may occur on the same day as transition from the parent study. All required parent study assessments must be complete, including the final evaluation of response to treatment (ERT; as defined in Assessments and procedures).
In addition, eligibility for participation in the LTFU study must have been determined, and informed consent/assent for participation in this LTFU study obtained. YCANTH (VP-102/TO-208) will be applied by the Investigator or qualified member of the research team to treatable common warts, including an approximate 1 to 2 mm margin of healthy, surrounding skin. After YCANTH (VP-102/TO- 208) is applied, warts are to be covered with occlusive tape (occlusive tape with similar properties should be used across all clinical sites) that will remain in place overnight and should be removed 24 hours after application of study drug and just before a 24-hour ERT. Before application of study drug, wart paring, if necessary, will be completed with a sharp surgical instrument (eg, scalpel or flexible medical blade) to remove any adherent thick scale from a treatable common wart. Wart paring is required to be performed at any treatment visit when adherent thick scale is present, and the Investigator feels paring can be safely performed. Paring should be conducted by a trained practitioner and in compliance with any local regulations and should be discontinued if it results in punctate bleeding or significant pain. Not all treatable common warts may require paring. If adherent scale is not present, study drug can be applied without paring. The assessment for complete clearance may be made once all treatable common warts are evaluable and not obscured by an ongoing LSR. If the Investigator is unable to evaluate or treat 1 or more warts due to ongoing LSRs, no warts should be treated, and the visit will be documented as an Unscheduled Visit. The timing of the next treatment visit will be determined by resolution of the LSRs. The research team will be in contact with the Participant until all LSRs are resolved. Once LSRs have resolved, a Treatment Visit will be scheduled within 21 (± 4) days of the previous treatment application, noting it may be longer than 21 (± 4) days depending on the length of time until LSR resolution. All treatable common warts that are not completely clear should undergo treatment with study drug. Study duration from Days 84, 105, or 147 of the parent study (COVE-2 or COVE-3) through the final EOS visit of this LTFU study (Day 378) is approximately 294 days.

Start Date11 Mar 2026

Sponsor / Collaborator

Verrica Pharmaceuticals, Inc.

[+5]

NCT07246590

/ RecruitingPhase 3

COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.

Start Date17 Dec 2025

Sponsor / Collaborator

Verrica Pharmaceuticals, Inc.

[+4]

100 Clinical Results associated with Cantharidin

100 Translational Medicine associated with Cantharidin

100 Patents (Medical) associated with Cantharidin

1,132

Literatures (Medical) associated with Cantharidin

01 Jul 2026·ARCHIVES OF TOXICOLOGY

CYP2C19 as a key enzyme in the metabolism of cantharidin in Huh-7 cells and mice

Article

Author: Liu, Yijia ; Zhang, Jie ; Ma, Jinghong ; Wang, Qing K ; Liu, Liang ; Song, Kaiyin ; Yao, Yufeng ; Lyu, Feng ; Zhou, Xiaowei ; Tian, Tongtong ; Wu, Yifan

Cantharidin (CTD), a traditional Chinese medicinal with a long history of use, exhibits broad-spectrum antitumor properties. However, its clinical application is severely limited by its inherent toxicity. Cytochrome P450 (CYP) enzymes are major phase I drug-metabolizing enzymes in clinical settings. To date, however, no enzymes responsible for the metabolism of CTD have been reported yet. In this study, specific CYP450 isoforms involved in CTD metabolism were identified and validated. We first performed in vitro experiments using Huh-7 cells to screen for enzymes capable of metabolizing CTD. Subsequent in vivo studies were conducted by tail vein injection of adeno-associated virus (AAV8-CYP2C19) to achieve CYP2C19 overexpression in mice. Mice were then administered CTD (1.5 mg/kg) by gavage, and survival was monitored. Cardiac injury was evaluated using Hematoxylin-Eosin (HE) staining and Masson staining, while cardiac function was assessed by echocardiography. Myocardial apoptosis was examined by TUNEL staining and Western blotting. The expression levels of genes encoding related enzymes were measured by Real-Time quantitative PCR. GC-MS was employed to quantify CTD concentrations in cell culture medium, mouse blood, and mouse liver tissues. Additionally, single-nucleotide polymorphism (SNP) analysis was performed on human samples. Our in vitro results identified CYP2C19 as a key enzyme involved in CTD metabolism. Consistent with this, AAV8-CYP2C19‑mediated overexpression in mice significantly accelerated CTD metabolism. CTD administration induced cardiac dysfunction, particularly within 6 h of gavage, as evidenced by a rapid decline in cardiac output. Histological analysis revealed myocardial damage characterized by inflammatory cell infiltration and collagen fiber deposition. TUNEL staining and Western blotting further confirmed increased cardiomyocyte apoptosis following CTD exposure. GC-MS analysis demonstrated reduced CTD concentrations in the blood and liver of AAV8‑CYP2C19‑treated mice, which corresponded to alleviated myocardial injury in the AAV8-CYP2C19 + CTD group. In human samples, liver samples from patients who died of CTD-induced toxicity were found to carry the CYP2C19*2 SNP, a variant associated with the slow-metabolizer phenotype. Collectively, our findings demonstrate, for the first time, that CTD is metabolized by CYP2C19. These results suggest that genetic testing for CYP2C19 polymorphisms could be performed prior to CTD-based cancer therapy, thereby facilitating precision medicine approaches that minimize toxicity and improve therapeutic efficacy.

20 May 2026·BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

Compounds identified by screening that inhibit the activity of transcription factor FOXO1/3a suppress dexamethasone-induced atrogin1 expression in C2C12 myoblasts

Article

Author: Oyabu, Mamoru ; Kamei, Yasutomi ; Yamamoto, Arisa ; Onishi, Takumi ; Sakaue, Manato

Abstract:

Using a reporter assay system we screened a library of 472 compounds, and identified 1,25(OH)2D3, all-trans-retinoic acid, 9-cis-retinoic acid, 13-cis-retinoic acid, 17-allylamino-17-demethoxygeldanamycin, cantharidin, and magnolol that inhibit FOXO1/3a activity. These compounds suppressed the increase in Atrogin1 gene expression induced by dexamethasone in C2C12 myoblasts. Therefore, these compounds may prevent muscle atrophy by inhibiting FOXO1/3a activity.

01 Apr 2026·BIOCHEMICAL PHARMACOLOGY

Integrative analyses of network pharmacology and bioinformatics reveal the synergistic antitumor effects of cantharidin and ginsenosides Rg3 on hepatocellular carcinoma

Article

Author: Wang, Yuehua ; Yan, Jia ; Chen, Jie ; Gou, Xianggang ; Wang, Ziyao ; Yuan, Henye ; Wang, Haisheng ; Zhou, Zhongzheng ; Yan, Wei

Cantharidin (CTD) has been traditionally used in Traditional Chinese Medicine (TCM) and exhibits pronounced antitumor activity, particularly in hepatocellular carcinoma (HCC). However, its preclinical translation has been substantially constrained by dose-limiting toxicity. Inspired by traditional Mylabris and Ginseng combinations, we conducted an investigation into the synergistic efficacy of CTD and Ginsenoside-Rg3 (Rg3), one of the most prevalent and bioactive ginsenosides, in combating HCC. We find that CTD/Rg3 co-treatment synergistically suppressed HCC cell proliferation, migration, and invasion. Mechanistically, an integrated multi-omics approach analyses illuminated the involvement of multi-target and multi-pathway mechanisms in CTD/Rg3 combination therapy for HCC. Function enrichment analyses reveal that targets of CTD/Rg3 were significantly associated with metabolic pathways and immune responses. Further screening identified AKR1D1, SLC16A4, and ALDH3B1 as potential drug targets. Subsequent correlation analysis with clinical data from liver cancer patients indicated that AKR1D1 and SLC16A4 were activated, whereas ALDH3B1 was inhibited, during CTD/Rg3 intervention in HCC progression. Molecular docking studies further demonstrated that both CTD and Rg3 bind with high affinity and stability to the active site of ALDH3B1, a molecule associated with immune microenvironment remodeling in HCC. Collectively, our findings demonstrate that CTD/Rg3 combination therapy exerts potent anti-HCC effects through multi-targeted mechanisms. By simultaneously modulating metabolic pathways and immune responses, this strategy represents a novel integrative approach for HCC treatment. These results not only elucidate the molecular basis of CTD/Rg3 efficacy but also provide robust preclinical support for its clinical translation in HCC management.

119

News (Medical) associated with Cantharidin

07 Aug 2026

·www.biospace.com

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations — — Facility provides potential for no scheduled interest or principal payments until maturity in December 2030 — — Facility provided by an entity controlled by Paul B. Manning, Verrica’s Chairman and largest shareholder — WEST CHESTER, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the closing of a credit facility of up to $27.5 million with an entity controlled by Paul B. Manning, Verrica’s largest shareholder. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “This facility provides Verrica with a meaningful source of non-dilutive capital and supports the continued growth of our YCANTH® business as well as the global Phase 3 program studying YCANTH for the treatment of common warts,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Importantly, this facility provides potential for no scheduled payments of interest or principal until maturity and did not include the issuance of any warrants. This flexibility will allow Verrica to maximize deployment of its cash resources toward advancing its business and pipeline. I would like to thank Paul Manning for his continued support of Verrica and for his confidence in our team to execute on our commercial and development initiatives.” Dr. Rieger continued, “We are seeing increasing adoption of YCANTH for molluscum and we have now secured the capital needed to advance the global Phase 3 common warts program, which includes two pivotal studies with data readouts expected by mid-2027. If approved, YCANTH could become the first FDA-approved therapy for the treatment of common warts, a condition affecting approximately 22 million patients in the US alone. We believe that a label expansion for YCANTH in common warts could represent a commercial opportunity several times larger than molluscum, given the unmet need and the millions of individuals impacted by this condition each year. Based on our current operating plan, we believe the full $27.5 million that may be available under the facility could extend our cash runway into 2028.” Paul B. Manning, Chairman and Chief Executive Officer of PBM Capital and Chairman of the Board of Directors of Verrica, commented, “I am proud to support Verrica’s continued growth by providing access to the additional capital it needs to achieve its goals. Verrica’s commercial performance has clearly strengthened over the last year, and I expect continued growth into the future. I have believed in the potential of YCANTH since I first invested in Verrica in 2015, and I am excited about what the future holds for Verrica, its shareholders and, most importantly, the patients it serves.” Terms of the Credit Agreement Under the terms of credit agreement, Verrica may borrow up to $12.5 million under the facility immediately, with an additional $15.0 million becoming available upon Verrica’s achievement of certain revenue, growth and other operational milestones, in each case subject to customary conditions. Borrowings under the facility will bear interest at the one-month secured overnight financing rate (SOFR) plus 8.00% per annum, subject to a SOFR floor of 4.50%. All interest under the facility will be payable in kind with a maturity date of December 31, 2030, subject to the absence of any event of default under the credit agreement (which results in interest being payable in cash and increased during the pendency of such event of default, unless otherwise elected by the lender). The credit agreement also requires mandatory prepayments with the proceeds of certain transactions and events, and quarterly payments if positive operating cash flow exceeds a specified amount. The credit facility is secured by substantially all of the assets of Verrica and certain subsidiaries. Additional information about the terms of the credit agreement can be found in Verrica’s Quarterly Report on Form 10-Q to be filed on August 6, 2026. About YCANTH® (VP-102) YCANTH ® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH in the US was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information. YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is also now being studied in a global phase 3 program in the US and Japan for use in the treatment of common warts. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about Verrrica’s ability to borrow funds under the credit facility, Verrica’s achievement of milestones set forth in the credit agreement, the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315, the timing of readouts from the Phase 3 common warts program and Verrica’s cash runway. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

Phase 3Drug ApprovalLicense out/inClinical Result

30 Jul 2026

·www.biospace.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss the Company's financial results for the second quarter ending June 30, 2026, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-225-9448 (domestic) or 1-203-518-9708 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register. A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, , or by clicking here . A replay of the webcast will be archived on Verrica’s website for 90 days following the event. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); FOR MORE INFORMATION, PLEASE CONTACT: Investors: John J Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

21 Jul 2026

·www.biospace.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement (“the Agreement”) granting Medomie Pharma Ltd. (“Medomie”) rights to seek regulatory approval for and distribute YCANTH ® for the treatment of molluscum contagiosum (“molluscum”) in Israel. “We are pleased to partner with Medomie to make YCANTH available in Israel so that more patients have access to treatment for molluscum,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Medomie is a pharmaceutical company focused on providing access to and commercializing innovative treatments, and improving health and quality of life of patients in Israel. We look forward to working with them as we seek to establish YCANTH as the standard of care for molluscum in Israel. Verrica maintains exclusive global rights to YCANTH for all indications outside of Japan and Israel, and we will continue our work to bring YCANTH to patients with molluscum around the world,” Dr. Rieger continued. Under the terms of the Agreement, Verrica has granted Medomie an exclusive right to obtain and maintain marketing authorizations for YCANTH in Israel. Verrica will manufacture YCANTH and provide commercial supply to Medomie and will receive 60% of the net selling price of product sold by Medomie in Israel. Verrica is also eligible to receive up to $8.2 million in total regulatory and commercial milestones. About YCANTH ® (VP-102) YCANTH ® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH in the US was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is also now being studied in a global phase 3 program in the US and Japan for use in the treatment of common warts. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about seeking regulatory approval and commercializing YCANTH in Israel, potential future payments pursuant to the Agreement and the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

100 Deals associated with Cantharidin

External Link

KEGG	Wiki	ATC	Drug Bank
D11745	Cantharidin	D11AF	DB12328

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Molluscum Contagiosum	United States	Verrica Pharmaceuticals, Inc.	21 Jul 2023
Condylomata Acuminata	China	Hainan Huiyuantang Pharmaceutical Co Ltd	10 Jul 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plantar wart	Phase 3	United States	Verrica Pharmaceuticals, Inc.	17 Dec 2025
Warts	Phase 3	Japan	Verrica Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAD2025	Phase 3	Molluscum Contagiosum	303	TO-208	zaikfbajsj(flbloghcyy) = vhrgxicrds sxhhuzrkxl (evcsfvlxiq ) View more	Positive	07 Mar 2025
				Placebo	zaikfbajsj(flbloghcyy) = nhkwrnrkwq sxhhuzrkxl (evcsfvlxiq ) View more
GlobeNewswire Manual	Phase 3	Molluscum Contagiosum	-	TO-208	iawefjeejw(tthtqfnbaw) = statistically significant versus placebo cepsducopb (avbsxvmofw )	Positive	15 Dec 2023
				Placebo
NCT03377803 \| NCT03377790 (FDA) Manual	Phase 3	Molluscum Contagiosum	528	YCANTH (Trial 1)	kcpsnapyel(xqmdxrbyig) = mjyzhyzjuy lflibrlmwd (ushyrfzdev ) View more	Positive	21 Jul 2023
				Vehicle (Trial 1)	kcpsnapyel(xqmdxrbyig) = fcqiglffxo lflibrlmwd (ushyrfzdev ) View more
NCT03377790 (CAMP-1, CTgov)	Phase 3	Molluscum Contagiosum	266	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	vdtctesjlv = iabpgywsst zdaqsgnfhk (wmhjqjkspo, sesoemoofx - jpbrufgdck) View more	-	14 Dec 2021
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	vdtctesjlv = mjmaagikto zdaqsgnfhk (wmhjqjkspo, iclvvtnwdc - eajaeyedoe) View more
NCT03377803 (CAMP-2, CTgov)	Phase 3	Molluscum Contagiosum	262	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	owmnpalcog = yobornjhyz uqtizqnmpt (npqfnonrqn, nzbthbptlz - prhyivkozv) View more	-	14 Dec 2021
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	owmnpalcog = jqehxgypdf uqtizqnmpt (npqfnonrqn, vjzqurouux - ejqexfxhox) View more
NCT03981822 (Pubmed \| Am J Clin Dermatol) Manual	Phase 2	Condylomata Acuminata	-	VP-102	zbvwlmkugy(idjqbeauht) = gtdpogshkr nmqdnjhkzy (roffrtkiug ) View more	Positive	01 Nov 2021
				Placebo	zbvwlmkugy(idjqbeauht) = gscqlnbvyt nmqdnjhkzy (roffrtkiug ) View more
NCT03487549 (COVE-1, Pubmed) Manual	Phase 2	Warts	56	VP-102 (Cohort 1)	vcgltllbxl(kwxsqgjxhz) = sjkulpjjck uqlwarkffo (nsdymoikbd )	Positive	01 Oct 2021
				VP-102 (Cohort 2)	vcgltllbxl(kwxsqgjxhz) = xvxctlbmty uqlwarkffo (nsdymoikbd )
NCT03981822 (CARE-1, CTgov)	Phase 2	Condylomata Acuminata	105	VP-102 (Part B Pooled With Part A: VP-102 6-hour)	hqlkacuioc: P-Value = 0.0048 View more	-	22 Sep 2021
				Placebo (Part B Pooled With Part A: Placebo 6-hour)
NCT03487549 (COVE-1, CTgov)	Phase 2	Warts	56	VP-102 (Cohort 1)	ojwoiklcbg = bwslpcofsv aubcayamar (fipahooidq, dohyurenxu - qjvzvtkuvh) View more	-	01 Sep 2021
				VP-102 (VP-102 - Cohort 2)	eelhaetqrv = wirhhsqggo oyjevqyonz (anohzdejyk, llfahcrzqv - nqouhzfsdn) View more
NCT03186378 (CTgov)	Phase 2	Molluscum Contagiosum	33	VP-102 with applicator (Exposure Group)	epxqxqnfhh = thqnhfangh phjufkiuri (hzcufpxghn, uyfnhshtce - ujygyvbbws) View more	-	09 Aug 2021
				VP-102 with applicator (Standard Group)	epxqxqnfhh = witnyprses phjufkiuri (hzcufpxghn, vehorzworu - giklenkhka) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis